Integral Diagnostics Limited

CHIA:IDX Stock Report

Market Cap: AU$697.1m

Integral Diagnostics Past Earnings Performance

Past criteria checks 0/6

Integral Diagnostics's earnings have been declining at an average annual rate of -47.6%, while the Healthcare industry saw earnings declining at 3.3% annually. Revenues have been growing at an average rate of 13.8% per year.

Key information

-47.6%

Earnings growth rate

-48.7%

EPS growth rate

Healthcare Industry Growth2.4%
Revenue growth rate13.8%
Return on equity-20.1%
Net Margin-12.9%
Next Earnings Update25 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Integral Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CHIA:IDX Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24470-612715
31 Mar 24463-592614
31 Dec 23456-58260
30 Sep 23449-16260
30 Jun 23441252513
31 Mar 2341823246
31 Dec 2239521220
30 Sep 2237818210
30 Jun 2236115210
31 Mar 2236118210
31 Dec 2136022220
30 Sep 2135626220
30 Jun 2135131220
31 Mar 2133332210
31 Dec 2031532190
30 Sep 2029528180
30 Jun 2027623160
31 Mar 2026322180
31 Dec 1925021190
30 Sep 1924121210
30 Jun 1923221240
31 Mar 1922219230
31 Dec 1821117230
30 Sep 1820016220
30 Jun 1818915210
31 Mar 1818715210
31 Dec 1718515200
30 Sep 1718215200
30 Jun 1718015200
31 Mar 1717716190
31 Dec 1617516190
30 Sep 1617114180
30 Jun 1616811180
31 Mar 1616511170
31 Dec 1516211170
30 Sep 151578170
30 Jun 151515160
30 Jun 144310

Quality Earnings: IDX is currently unprofitable.

Growing Profit Margin: IDX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IDX is unprofitable, and losses have increased over the past 5 years at a rate of 47.6% per year.

Accelerating Growth: Unable to compare IDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IDX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-25.4%).


Return on Equity

High ROE: IDX has a negative Return on Equity (-20.12%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 18:11
End of Day Share Price 2025/01/10 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Integral Diagnostics Limited is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightBarclay Pearce Capital Pty Limited
Thomas YeoBarrenjoey Markets Pty Limited
Saul HadassinBarrenjoey Markets Pty Limited